Black Diamond Therapeutics (BDTX) Price to Book (2020 - 2026)

Black Diamond Therapeutics (BDTX) has reported Price to Book for 7 consecutive years, with 1.11 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 3.96% year-over-year to 1.11; the trailing twelve-month figure through Jun 2026 stood at 1.11 (up 3.96% YoY), and the FY2025 full-year result was 1.24, down 14.99% from the prior year.
• Price to Book eased to 1.11 in Q2 2026 per BDTX's latest filing, from 1.17 in the prior quarter.
• Across five years, Price to Book topped out at 2.55 in Q1 2024 and bottomed at 0.46 in Q3 2022.
• Historically, Price to Book has averaged 1.3 across 5 years, with a median of 1.14 in 2026.
• The sharpest annual moves came in 2022 and 2023: Price to Book slumped 81.35% in 2022, then surged 282.81% in 2023.
• Over 5 years, Price to Book stood at 0.57 in 2022, then soared by 119.31% to 1.24 in 2023, then grew by 17.08% to 1.46 in 2024, then declined by 14.99% to 1.24 in 2025, then fell by 10.62% to 1.11 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 1.11, 1.17, and 1.24 for Q2 2026, Q1 2026, and Q4 2025 respectively.